Market Overview

UPDATE: Jefferies Raises PT on Pfizer on Attractive Valuation

Share:
Related PFE
Guggenheim Introduces Equal-Weight S&P 100 ETF
Could Chili Peppers Be The Answer To Opioid-Reliance For Chronic Pain?
2 Top Stocks Offer Healthy, Stable Dividends (Investor's Business Daily)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Pfizer (NYSE: PFE), and raised the price target from $31.00 to $33.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Pfizer closed on Tuesday at $29.11.

Latest Ratings for PFE

DateFirmActionFromTo
Jun 2016JefferiesMaintainsBuy
Jun 2016JefferiesMaintainsBuy
May 2016BerenbergInitiates Coverage onHold

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (PFE)

View Comments and Join the Discussion!